D. Kim

发表

D. Cella, J. Lipton, C. Powell, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bosutinib (BOS) versus imatinib (IM) in patients (pts) with chronic phase chronic myeloid leukemia (CP CML) in the BELA trial: 18-month follow-up.

Patricia L. Harris, T. Brümmendorf, H. Kantarjian, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bosutinib (BOS) as third-line therapy for chronic phase (CP) chronic myeloid leukemia (CML) following failure with imatinib (IM) and dasatinib (DAS) or nilotinib (NIL).

M. Baccarani, H. Kantarjian, J. Cortes, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005.

A. Bottomley, A. Shaw, T. Mok, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparative analyses of overall survival of anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) patients who did not receive ALK inhibitors.

D. Heo, W. H. Kim, H. Park, 2011, Journal of Clinical Oncology.

GEM technical design report

Joseph A. Paradiso, G. C. Fox, D. Crosetto, 1993 .

Efficacy of chemotherapy as a first-line treatment in ocular adnexal extranodal marginal zone B-cell lymphoma.

D. Heo, S. Khwarg, S. H. Lee, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

1225OOVERALL AND INTRACRANIAL (IC) EFFICACY RESULTS AND TIME TO SYMPTOM DETERIORATION IN PROFILE 1014: 1ST-LINE CRIZOTINIB VS PEMETREXED - PLATINUM CHEMOTHERAPY (PPC) IN PATIENTS (PTS) WITH ADVANCED ALK-POSITIVE NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC).

T. Mok, K. Wilner, E. Felip, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

1293PEVALUATION OF CERITINIB-TREATED PATIENTS (PTS) WITH ANAPLASTIC LYMPHOMA KINASE REARRANGED (ALK+) NON-SMALL CELL LUNG CANCER (NSCLC) AND BRAIN METASTASES IN THE ASCEND-1 STUDY.

A. Shaw, Gregory Riely, E. Felip, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Dasatinib (D) in patients (pts) with chronic myelogenous leukemia (CML) in myeloid blast crisis (MBC) who are imatinib-resistant (IM-R) or IM-intolerant (IM-I): Results of the CA180006 'START-B' study.

C. Sawyers, J. Cortes, P. Rousselot, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia

A. Nagler, I. Dufva, G. Martinelli, 2014, Blood Cancer Journal.

NAMPT Is an Essential Regulator of RA-Mediated Periodontal Inflammation

Gyuseok Lee, Y. Huh, J. Ryu, 2017, Journal of dental research.

Efficacy and Safety of Ceritinib in Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Rearranged (ALK+) Non-Small Cell Lung Cancer (NSCLC): An Update of ASCEND-1

Michael Thomas, A. Shaw, Gregory Riely, 2014 .

1295PEFFICACY AND SAFETY OF CERITINIB IN PATIENTS (PTS) WITH ADVANCED ANAPLASTIC LYMPHOMA KINASE (ALK)-REARRANGED (ALK+) NON-SMALL CELL LUNG CANCER (NSCLC): AN UPDATE OF ASCEND-1.

A. Shaw, Gregory Riely, E. Felip, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Tandem high-dose chemotherapy and autologous stem cell rescue in patients over 1 year of age with stage 4 neuroblastoma

Y. Suh, H. Koo, K. Yoo, 2007, Bone Marrow Transplantation.

European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia

C. Schiffer, R. Larson, M. Baccarani, 2020, Leukemia.

Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001

S. C. Wang, A. Iafrate, A. Shaw, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Tandem high-dose chemotherapy and autologous stem cell transplantation in patients with high-risk neuroblastoma: Results of SMC NB-2004 study

H. Koo, K. Yoo, D. Lim, 2013, Bone Marrow Transplantation.

Successive double high-dose chemotherapy with peripheral blood stem cell rescue collected during a single leukapheresis round in patients with high-risk pediatric solid tumors: a pilot study in a single center

H. Koo, K. Yoo, H. K. Park, 2003, Bone Marrow Transplantation.

Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial

Y. Shentu, R. Herbst, M. Ahn, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Induction chemotherapy with idarubicin plus N4-behenoyl-1-beta-D-arabinofuranosylcytosine in acute myelogenous leukemia: a newly designed induction regimen--a prospective, cooperative multicenter study.

H. Park, J. Park, H. Ahn, 1996, Seminars in hematology.

449PDUPDATED SAFETY AND EFFICACY FROM A PHASE I STUDY OF AZD9291 IN PATIENTS (PTS) WITH EGFR-TKI-RESISTANT NON-SMALL CELL LUNG CANCER (NSCLC).

M. Ranson, E. Felip, D. Planchard, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Proangiogenic effects of ionizing irradiation on squamous cell carcinoma of the hypopharynx.

W. Mann, J. Brieger, J. Hast, 2008, Auris, nasus, larynx.

A phase II trial of S-1 and cisplatin in patients with metastatic or relapsed biliary tract cancer.

Y. Bang, Y. Kim, J. Kim, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Antibiotic use during the last days of life in cancer patients.

Y. Bang, J. Kim, Dong-Wan Kim, 2006, European journal of cancer care.

Dasatinib dose-optimization study in chronic phase chronic myeloid leukemia (CML-CP): Three-year follow-up with dasatinib 100 mg once daily and landmark analysis of cytogenetic response and progression-free survival (PFS).

H. Kantarjian, R. Stone, P. Rousselot, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Angiogenesis and fibroblast proliferation precede formation of recurrent tumors after radiation therapy in nude mice.

F. Oesch, J. Hengstler, W. Mann, 2002, Anticancer research.

Comparison of nilotinib and imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 24-month follow-up.

R. Larson, H. Kantarjian, G. Saglio, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PF-00299804 (PF299) in Asian patients (pts) with non-small cell lung cancer (NSCLC) refractory to chemotherapy (CT) and erlotinib (E) or gefitinib (G): A phase (P) I/II study.

B. Cho, D. Heo, K. Park, 2010 .

Neoadjuvant docetaxel and cisplatin chemotherapy followed by local irradiation is highly active on locoregionally advanced squamous cell carcinoma of the head and neck

Soo-Geun Wang, Ho-Jin Shin, J. Chung, 2007, The Journal of Laryngology & Otology.

Gefitinib monotherapy in previously treated advanced non-small cell lung cancer (NSCLC): An immunohistochemical (IHC) analysis of EGFR and its downstream molecules.

Y. Bang, D. Heo, D. Chung, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

456PPRECLINICAL EVIDENCE AND CLINICAL CASES OF AZD9291 ACTIVITY IN EGFR-MUTANT NON-SMALL CELL LUNG CANCER (NSCLC) BRAIN METASTASES (BM).

P. Janne, D. Cross, P. Ballard, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Superiority of conventional intensity-modulated radiotherapy over helical tomotherapy in locally advanced non-small cell lung cancer

H. Pyo, Y. Lim, D. Kim, 2012, Strahlentherapie und Onkologie.

1293PEVALUATION OF CERITINIB-TREATED PATIENTS (PTS) WITH ANAPLASTIC LYMPHOMA KINASE REARRANGED (ALK+) NON-SMALL CELL LUNG CANCER (NSCLC) AND BRAIN METASTASES IN THE ASCEND-1 STUDY.

A. Shaw, Gregory Riely, E. Felip, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.